{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/prescribing-information/pioglitazone/","result":{"pageContext":{"chapter":{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone","depth":2,"htmlHeader":"<!-- begin field c62eb023-c3aa-410a-b869-d55cb7d9d7e7 --><h2>Pioglitazone</h2><!-- end field c62eb023-c3aa-410a-b869-d55cb7d9d7e7 -->","summary":"","htmlStringContent":"<!-- begin item 80282661-67d1-4c13-8443-f8f42a757f4f --><!-- end item 80282661-67d1-4c13-8443-f8f42a757f4f -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"197e7160-b49b-55e8-9b76-7433514e22c7","slug":"recommended-dose","fullItemName":"Recommended dose","depth":3,"htmlHeader":"<!-- begin field 91cb8e8b-37ea-4d75-8a79-f0d313530b04 --><h3>Recommended dose</h3><!-- end field 91cb8e8b-37ea-4d75-8a79-f0d313530b04 -->","summary":"","htmlStringContent":"<!-- begin item ce33c37a-2ba1-4e28-8e4d-f0cf2cdd3020 --><!-- begin field a0503815-033c-4fbb-ab7b-975316815572 --><ul><li><strong>Pioglitazone is the only glitazone currently available in the UK.</strong><ul><li>The recommended dose is 15–30 mg once daily, increased to 45 mg once daily, according to response. In elderly people, prescribe 15 mg once daily initially, and increase the dose gradually.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field a0503815-033c-4fbb-ab7b-975316815572 --><!-- end item ce33c37a-2ba1-4e28-8e4d-f0cf2cdd3020 -->","subChapters":[]},{"id":"8ed4dbc1-cebc-534d-8fb7-9e3effc8c8a9","slug":"initiating-monitoring","fullItemName":"Initiating and monitoring","depth":3,"htmlHeader":"<!-- begin field c07ca3d5-e3cf-4a63-b522-e7790f265c75 --><h3>Initiating and monitoring</h3><!-- end field c07ca3d5-e3cf-4a63-b522-e7790f265c75 -->","summary":"","htmlStringContent":"<!-- begin item c837a4b9-5485-445c-a12e-ecd2e2e60b9a --><!-- begin field 77a97483-ffe4-4d04-b08f-d97b88ee178f --><ul><li><strong>Before </strong><strong>starting treatment with pioglitazone:</strong><ul><li>Monitor liver function tests (LFTs).<ul><li>If alanine aminotransferase (ALT) is more than 2.5 times the upper limit of normal, or there is any other evidence of liver disease, do not start treatment.</li></ul></li><li>Assess the risk of heart failure and bone fracture. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure</a> and <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> for more information.</li><li>Assess the risk of bladder cancer. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/urological-cancers-recognition-referral/\">Urological cancers - recognition and referral</a> for more information. Risk factors include:<ul><li>Increasing age.</li><li>Current or past history of smoking.</li><li>Exposure to some occupational or chemotherapy drugs, such as cyclophosphamide.</li><li>Previous radiation therapy to the pelvic region.</li></ul></li></ul></li><li><strong>Following initiation of treatment with pioglitazone:</strong><ul><li>Monitor LFTs periodically, based on clinical judgement.</li><li>Monitor for signs and symptoms of heart failure, such as weight gain or oedema. <ul><li>Stop pioglitazone if any deterioration in cardiac function is seen.</li></ul></li><li>Assess the safety and efficacy of pioglitazone 3–6 months after treatment is initiated, and regularly thereafter.<ul><li>Stop pioglitazone in people who do not respond adequately to treatment.</li><li>Advise the person to seek urgent medical assessment if any symptoms or signs of bladder cancer develop. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/urological-cancers-recognition-referral/\">Urological cancers - recognition and referral</a> for more information.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 77a97483-ffe4-4d04-b08f-d97b88ee178f --><!-- end item c837a4b9-5485-445c-a12e-ecd2e2e60b9a -->","subChapters":[]},{"id":"d35c8256-44cd-5559-a3a8-7fb70e77466f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 66910be4-c01e-40ad-a61b-7340b454de85 --><h3>Contraindications and cautions</h3><!-- end field 66910be4-c01e-40ad-a61b-7340b454de85 -->","summary":"","htmlStringContent":"<!-- begin item 160c48f3-ed93-490a-b0f1-23e9ffe376f7 --><!-- begin field abfe18d4-5d9e-4f51-9866-5669565999c0 --><ul><li><strong>Do not prescribe pioglitazone to people with:</strong><ul><li>Heart failure or a history of heart failure.</li><li>Uninvestigated macroscopic haematuria.</li><li>Previous or active bladder cancer.</li><li>Hepatic impairment.</li></ul></li><li><strong>Prescribe pioglitazone with caution to people:</strong><ul><li>Who are elderly — increased risk of bladder cancer, heart failure, and fracture.</li><li>Who also use insulin — increased risk of heart failure.</li><li>Risk factors for bladder cancer. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/urological-cancers-recognition-referral/\">Urological cancers - recognition and referral</a>.</li><li>Risk factors for heart failure (such as previous myocardial infarction, cardiovascular disease). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a> for more information.</li><li>Risk factors for bone fracture. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> for more information.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field abfe18d4-5d9e-4f51-9866-5669565999c0 --><!-- end item 160c48f3-ed93-490a-b0f1-23e9ffe376f7 -->","subChapters":[]},{"id":"c6f756ab-4fa1-5a22-b39f-40f5def5d408","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e104acee-1d8b-4fc1-b561-c58afb84aafd --><h3>Adverse effects</h3><!-- end field e104acee-1d8b-4fc1-b561-c58afb84aafd -->","summary":"","htmlStringContent":"<!-- begin item 82690b42-0723-40d5-83c3-0ab784a1c38e --><!-- begin field aff018be-ac4f-4fb5-bd37-27173990c0f3 --><p><strong>Possible adverse effects of pioglitazone include:</strong></p><ul><li>Numbness, visual impairment, weight increase, insomnia.</li><li>Increased risk of bone fractures.</li><li>Increased risk of infection.</li><li>Bladder cancer.</li><li>Hepatic impairment (rare) — stop pioglitazone if jaundice occurs. Seek immediate medical advice if symptoms such as nausea, vomiting, abdominal pain, fatigue, and dark urine develop.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field aff018be-ac4f-4fb5-bd37-27173990c0f3 --><!-- end item 82690b42-0723-40d5-83c3-0ab784a1c38e -->","subChapters":[]},{"id":"e0d63804-517e-53c7-bd7b-e3131f233e54","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 317c6791-3bdb-4ea6-9996-22c53b192f8a --><h3>Drug interactions</h3><!-- end field 317c6791-3bdb-4ea6-9996-22c53b192f8a -->","summary":"","htmlStringContent":"<!-- begin item 65558c70-4580-484f-b106-367036357e16 --><!-- begin field 7fd0a2cc-1a60-42a6-83de-1f7b922db384 --><ul><li><strong>Potential drug interactions associated with pioglitazone include:</strong><ul><li>Beta-blockers — the warning signs of hypoglycaemia (such as tremor) may be masked when pioglitazone is given with a beta-blocker.</li><li>Gemfibrozil — can significantly increase the plasma concentration of pioglitazone. Consider reducing the dose of pioglitazone.</li><li>Ketoconazole — the plasma concentration of pioglitazone may be increased by ketoconazole.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) — post marketing cases of peripheral oedema and cardiac failure have been reported. Discontinue pioglitazone if any deterioration in cardiac status occurs.</li><li>Liver enzyme-inducing drugs — rifampicin can significantly reduce the plasma concentration of pioglitazone (and the pioglitazone dose may need to be increased). Closely monitor blood glucose control during concurrent use of pioglitazone and other liver enzyme-inducers, such as phenytoin, carbamazepine, and St John's wort, as these may also affect the plasma concentration of pioglitazone.</li><li>Other antidiabetic drugs — people taking pioglitazone in dual or triple oral therapy with a sulfonylurea may be at increased risk of hypoglycaemia. It may be necessary to reduce the dose of the sulfonylurea.</li></ul></li><li><strong>In addition: </strong><ul><li><strong>The blood glucose-lowering effects of pioglitazone may be enhanced by: </strong><ul><li>Alcohol.</li><li>Anabolic steroids. </li><li>Monoamine oxidase inhibitors (MAOIs).</li><li>Testosterone. </li></ul></li><li><strong>The blood glucose-lowering effects of </strong><strong>pioglitazone may be antagonized by: </strong><ul><li>Corticosteroids. </li><li>Diuretics (thiazide and related, and loop). </li><li>Oestrogens and progestogens.</li></ul></li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 7fd0a2cc-1a60-42a6-83de-1f7b922db384 --><!-- end item 65558c70-4580-484f-b106-367036357e16 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}